- Conditions
- Chronic Kidney Disease, Heart Failure With Preserved Ejection Fraction (HFPEF), Obesity (Disorder)
- Interventions
- High protein and sodium meal
- Other
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 245
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diastolic Heart Failure, Hypertensive Heart Disease, Heart Failure With Preserved Ejection Fraction, Hypertension, Oxidative Stress
- Interventions
- grape seed extract (MegaNatural BP, Polyphenolics, Inc.)
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Heart Failure With Preserved Ejection Fraction, Hypertension
- Interventions
- Amlodipine Besylate, Metoprolol Succinate
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Fontan Circulation, Single Ventricle Heart Disease, HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Dapagliflozin tablet, Placebo Tablet
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Potassium Nitrate, Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside, Potassium Chloride
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
- Interventions
- 15-minutes of sitting during COR ECG Acquistion
- Device
- Lead sponsor
- Peerbridge Health, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Orange, California • Pasadena, California • Detroit, Michigan + 5 more
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases
- Interventions
- CRD-740, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 17
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 13 more
- Conditions
- Type 2 Diabetes, Heart Failure
- Interventions
- Tirzepatide, Semaglutide
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26,000 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
- Interventions
- Dobutamine, Amlodipine
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Heart Failure, Diastolic
- Interventions
- PowerBreathe (Breathing muscle training)
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
- Interventions
- MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
- Drug
- Lead sponsor
- Horng Chen
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- beta blocker discontinuation
- Other
- Lead sponsor
- UConn Health
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Farmington, Connecticut
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- Weight loss SOC Treatment with second generation anti-diabetic medications
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- HEART Camp Connect
- Behavioral
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Type 2 Diabetes, Heart Failure
- Interventions
- Oral semaglutide, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,664 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
- Interventions
- Semaglutide, Placebo (Semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 54
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Beverly Hills, California + 47 more
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 3 more
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- EDG-15400 25 mg, Placebo to match EDG-15400 25 mg or 50 mg, EDG-15400 50 mg
- Drug
- Lead sponsor
- Edgewise Therapeutics, Inc.
- Industry
- Eligibility
- 30 Years to 84 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 23 more
- Conditions
- Heart Failure, Heart Failure, Diastolic
- Interventions
- Corvia Atrial Shunt System / IASD System II, Intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
- Device · Other
- Lead sponsor
- Corvia Medical
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • La Jolla, California • Long Beach, California + 28 more
- Conditions
- Heart Failure, Congestive
- Interventions
- Istaroxime, Exercise
- Drug · Other
- Lead sponsor
- Benjamin Levine
- Other
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure, Obesity, Weight Loss, Heart Failure With Preserved Ejection Fraction
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Obesity, Heart Failure With Normal Ejection Fraction
- Interventions
- UFA dietary recommendations
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Heart Failure
- Interventions
- Finerenone (BAY94-8862), Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 6,016 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
- Conditions
- Heart Failure, Healthy Volunteer
- Interventions
- AMG 986 IV, AMG 986 PO, Placebo PO, Placebo IV
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- Anaheim, California • Tustin, California • Jacksonville, Florida + 5 more